• Market analysts predict monoclonal antibodies (“mAbs”) will be the fastest-growing revenue segment of the biologics medicinal market through the end of the decade
• BiondVax Pharmaceuticals is focused on developing and commercializing novel mAb “biobetter” NanoAbs to meet underserved medical needs addressing large market disorders
• The company’s recent work with an inhaled nanosized antibody for COVID has shown exceptionally promising results, virtually preventing illness and eliminating the SARS-COV-2 virus in a hamster population
• With COVID as first target, the company’s pipeline aims to provide effective medical responses to other disorders such asthma, psoriasis, psoriatic arthritis, and macular degeneration

Immunotherapeutic product innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) is focused on developing, manufacturing, and commercializing innovative nanosized antibodies (NanoAbs) for the treatment of infectious diseases and autoimmune diseases, stepping up its pursuit of disrupting the monoclonal antibody (“mAb”) market amid forecasts that the global mAb market will grow at a compound annual rate (“CAGR”) of 11.30 percent through 2030.

Grand View Research analysts reported recently that the global mAbs market size at the end of 2021 was valued at $185.50 billion and $210.06 billion by the end of 2022, with expectations it will reach $494.53 billion in revenues during the next eight years (https://ibn.fm/ki8n5).

BiondVax’s recent work with innovative “biobetter” NanoAb therapies in diseases underserved by current mAb treatments has led to exceptionally promising results from a preclinical proof-of-concept study of its inhaled COVID-19 therapy, in which it virtually eliminated SARS-COV-2 virus in the lungs, and led to significantly shorter and milder illness, according to the company (https://ibn.fm/s598q). Additional results of the preclinical study also showed promising prophylactic results with the potential to provide proactive protection for at risk patients.

“We continue to be thrilled with the results of this ongoing trial,” stated Amir Reichman, BiondVax’s CEO. (https://ibn.fm/q7ltP). “There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion. EVUSHELD is currently the only prophylactic COVID medication with FDA approval, under emergency use authorization. Our inhaled NanoAb is designed to be self-administered at the time of choosing to generate rapid protection from COVID illness. In contrast, EVUSHELD must be administered via two separate consecutive intramuscular (‘IM’) injections in a health care setting… we believe the additional ‘biobetter’ value provided by our NanoAb potentially positions it to capture significant market share both for treatment and prevention of COVID illness.”

Its important to note that recent data show EVUSHELD is unlikely to be active against certain SARS-CoV-2 variants and as of January 26, 2023, EVUSHELD is no longer authorized by the FDA for use in the U.S. (https://ibn.fm/fCEc6). AstraZeneca reported that EVUSHELD had generated $1.451 billion in revenue from Q1 through Q3 2022 (https://ibn.fm/bBAGS). BiondVax aims to fill the growing void in COVID prophylactics and therapeutics.

BiondVax’s pipeline of NanoAbs is expected to provide biologics that interact with previously validated therapeutic targets and have strong potential for significant advantages over currently approved human mAbs.

“NanoAbs being generated at MPI demonstrate several unique attributes such as greater binding affinity, stability at high temperatures, and formulation advantages,” Reichman stated. “We believe that if NanoAbs with these attributes can be successfully developed they would provide an opportunity to capture a meaningful share of several large and growing markets while reducing upfront costs and risks commonly associated with new drug development (e.g., biological target validation) and accelerating initiation of clinical development.”

There’s and old adage that ‘good things come in small packages’ and indications are that BiondVax’s NanoAbs may soon prove the adage true.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.